Smith & Nephew plc (SN) Fair Value & Analysis
Healthcare · GB · Market cap 9.3B GBX
Fair value as of: Jun 24, 2026
From 25 valuation models · updated 5 days ago
Fair value updated Jun 24, 2026 — revised from £14.19 to £14.36 (+1.2%) since Jun 23, 2026. Share price +2.9% over the past month.
Price vs Fair Value (12 months)
12‑month range £10.47 – £13.71 · fair‑value band £8.24 – £20.65 · the £11.18 price screens below the £14.36 fair value. As of Jun 24, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Smith & Nephew plc (SN) currently trades at £11.18, while our model-based Fair Value estimate is £14.36 — implying the stock looks roughly 28.4% undervalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high) — always confirm before acting.
Over the trailing twelve months, Smith & Nephew plc generated revenue of £6.2B at a net margin of 10.1%. Revenue grew 7.4% year over year. It earns a return on equity of 11.8%. Net debt stands at £2.8B. Fundamentals as of Jun 24, 2026
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jun 24, 2026. TTM = trailing twelve months.
About the company
Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom, the United States, and internationally. The company operates in three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. It offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products. The company also provides sports medicine joint repair products comprise instruments, technologies, and implants to perform minimally invasive surgery, as well as treating soft tissue injuries and degenerative conditions of the shoulder, knee, hip, and small joints. In addition, it provides arthroscopic enabling technologies comprising fluid management equipment for surgical access, cameras, digital ima…
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Smith & Nephew plc reported revenue of £6.3B in FY2025 versus £5.2B in FY2021, a compound +4.8%/yr. Reported net income was £638M in FY2025, compounding +5.0%/yr from FY2021.
Open the full interactive analysis →
Similar stocks
6 more Medical Devices stocks, each showing price versus our Fair Value estimate (as of Jun 24, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Abbott Laboratories, ABT | 1,600 MXN | 1,228 MXN | -23% |
| Stryker Corporation S1YK34 | R$77.83 | R$8.47 | -89% |
| Medtronic plc MDT | $80.25 | $74.40 | -7% |
| Boston Scientific Corporation B1SX34 | R$248.75 | R$221.81 | -11% |
| Edwards Lifesciences Corporation EW | $85.88 | $41.02 | -52% |
| Siemens Healthineers AG SEMHF | $39.95 | $44.36 | +11% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Smith & Nephew plc (SN) undervalued?
What is the fair value of SN?
What is the quality score of SN?
What is the revenue of Smith & Nephew plc (SN)?
What is the net profit margin of SN?
Does Smith & Nephew plc pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.